Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (peritubular myoid cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: fianlimab, eftilagimod alfa, ieramilimab +3 | 0.90 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 35 Parkinson's papers of 3,538 | 0.53 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2565
Sealed predictions
- LAG3 in dopamine neurons, braak-0.78 (p 0.012) → +0.12 (p 0.756)receipt 2572
Swarm cases
receipt 2572: LAG3 in dopamine neurons, braak
- power
- full sample -0.31 (p 0.211, n 18), 95% CI -0.68 to +0.18. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.188, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.63 (p 0.0047, n 18). not the mix.
- skeptic
- leave-one-out range -0.42 to -0.22, sign flips 0; without severely affected donors -0.31 (p 0.211, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LAG3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts